Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,844
  • Shares Outstanding, K 45,755
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -71,060 K
  • 60-Month Beta 2.75
  • Price/Sales 4.93
  • Price/Cash Flow N/A
  • Price/Book 0.23
Trade SNTI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.51
  • Most Recent Earnings $-0.26 on 05/09/24
  • Next Earnings Date 08/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +237,957.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2111 +84.75%
on 06/03/24
0.6100 -36.07%
on 07/01/24
+0.0900 (+30.00%)
since 05/31/24
3-Month
0.2111 +84.75%
on 06/03/24
0.6100 -36.07%
on 07/01/24
+0.0410 (+11.75%)
since 04/02/24
52-Week
0.2111 +84.75%
on 06/03/24
1.0900 -64.22%
on 08/03/23
-0.2370 (-37.80%)
since 06/30/23

Most Recent Stories

More News
Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection...

BBAI : 1.4500 (-0.68%)
SNTI : 0.3900 (-6.59%)
TNGX : 8.10 (-9.94%)
BOXD : 0.1898 (-15.27%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dynamics Special Purpose Corp., which merged with Senti Bioscience, Inc. ("Senti"...

SNTI : 0.3900 (-6.59%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
SNTI : 0.3900 (-6.59%)
INBX : 13.56 (-1.31%)
IMVT : 26.52 (-3.60%)
AUTL : 3.38 (-2.59%)
BMY : 40.45 (-2.06%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 40.45 (-2.06%)
ONC.TO : 1.37 (+1.48%)
ONCY : 0.9900 (-0.52%)
SNTI : 0.3900 (-6.59%)
INBX : 13.56 (-1.31%)
IMVT : 26.52 (-3.60%)
AUTL : 3.38 (-2.59%)
Chardan Announces Launch of ChEF (Chardan Equity Facility)

/PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution...

SNTI : 0.3900 (-6.59%)
CNTQ : 14.00 (-8.14%)

Business Summary

Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 0.4869
2nd Resistance Point 0.4463
1st Resistance Point 0.4181
Last Price 0.3900
1st Support Level 0.3493
2nd Support Level 0.3087
3rd Support Level 0.2805

See More

52-Week High 1.0900
Fibonacci 61.8% 0.7543
Fibonacci 50% 0.6506
Fibonacci 38.2% 0.5468
Last Price 0.3900
52-Week Low 0.2111

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar